NovoCure Limited (NVCR)
Healthcare • Medical Devices
StockNasdaqGSSwitzerlandJE00BYSS4X48
11.63 USD
-0.77% today Updated 13 Nov 2026 15:30
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by NovoCure Limited, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:30. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
25 Feb 2027
in 104 days · 08:00 · estimate -0.21
Last results
-0.09 vs -0.23 estimated
29 Oct 2026 · Beat +61.7%
Beat the estimate
10 of 12
2 missed · 0 in line · 2 beats in a row
Average surprise
+16.7%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 08:00 | -0.21 | — | — | Upcoming |
| 29 Oct 2026 07:00 | -0.23 | -0.09 | +61.7% | Beat |
| 23 Jul 2026 07:00 | -0.33 | -0.13 | +60.8% | Beat |
| 30 Apr 2026 07:00 | -0.51 | -0.62 | -20.9% | Miss |
| 26 Feb 2026 07:00 | -0.41 | -0.22 | +46.5% | Beat |
| 30 Oct 2025 06:00 | -0.42 | -0.33 | +21.4% | Beat |
| 24 Jul 2025 07:00 | -0.39 | -0.36 | +7.4% | Beat |
| 24 Apr 2025 07:00 | -0.46 | -0.31 | +33.2% | Beat |
| 27 Feb 2025 07:00 | -0.34 | -0.61 | -77.1% | Miss |
| 30 Oct 2024 07:00 | -0.33 | -0.28 | +16.2% | Beat |
| 25 Jul 2024 07:00 | -0.40 | -0.31 | +23.1% | Beat |
| 02 May 2024 07:00 | -0.42 | -0.36 | +14.2% | Beat |
| 22 Feb 2024 07:00 | -0.52 | -0.45 | +13.7% | Beat |
| 26 Oct 2023 07:00 | -0.52 | -0.46 | +12.4% | Beat |
| 27 Jul 2023 07:00 | -0.50 | -0.54 | -8.0% | Miss |
| 04 May 2023 07:00 | -0.34 | -0.50 | -47.1% | Miss |
| 23 Feb 2023 07:00 | -0.31 | -0.36 | -15.3% | Miss |
| 27 Oct 2022 07:00 | -0.26 | -0.25 | +2.8% | Beat |
| 28 Jul 2022 07:00 | -0.14 | -0.23 | -59.3% | Miss |
| 28 Apr 2022 07:00 | -0.19 | -0.04 | +79.1% | Beat |
| 24 Feb 2022 06:00 | -0.10 | -0.25 | -144.5% | Miss |
| 28 Oct 2021 06:00 | -0.06 | -0.13 | -106.6% | Miss |
| 29 Jul 2021 06:00 | 0.01 | -0.14 | -1,698.2% | Miss |
| 29 Apr 2021 06:00 | 0.01 | -0.04 | -411.0% | Miss |
| 25 Feb 2021 06:00 | 0.13 | 0.05 | -60.2% | Miss |
| 29 Oct 2020 06:00 | 0.04 | 0.09 | +129.4% | Beat |
| 30 Jul 2020 06:00 | 0.01 | 0.02 | +287.6% | Beat |
| 30 Apr 2020 07:00 | 0.03 | 0.04 | +17.7% | Beat |
| 27 Feb 2020 06:00 | — | 0.04 | +900.0% | Beat |
| 31 Oct 2019 06:00 | -0.04 | 0.02 | +154.9% | Beat |
| 25 Jul 2019 06:00 | -0.06 | -0.01 | +84.4% | Beat |
| 02 May 2019 06:00 | -0.15 | -0.13 | +11.2% | Beat |
| 28 Feb 2019 06:00 | -0.13 | -0.17 | -29.5% | Miss |
| 25 Oct 2018 06:00 | -0.14 | -0.13 | +7.7% | Beat |
| 26 Jul 2018 06:00 | -0.16 | -0.17 | -5.8% | Miss |
| 26 Apr 2018 06:00 | -0.13 | -0.23 | -73.9% | Miss |
| 22 Feb 2018 06:00 | -0.12 | -0.12 | +1.2% | Beat |
| 26 Oct 2017 06:00 | -0.14 | -0.13 | +9.0% | Beat |
| 27 Jul 2017 06:00 | -0.22 | -0.24 | -11.1% | Miss |
| 27 Apr 2017 06:00 | -0.20 | -0.21 | -3.7% | Miss |
| 23 Feb 2017 06:00 | -0.37 | -0.26 | +30.0% | Beat |
| 02 Nov 2016 06:00 | -0.31 | -0.39 | -23.8% | Miss |
| 28 Jul 2016 06:00 | -0.33 | -0.40 | -20.7% | Miss |
| 09 May 2016 16:00 | -0.32 | -0.42 | -29.2% | Miss |
| 29 Feb 2016 16:00 | -0.34 | -0.24 | +29.3% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 655.4M | +8.3% | -136.2M | -20.8% | -1.22 | +21.8% | -75.7M |
| 2024 | 605.2M | +18.8% | -168.6M | -27.9% | -1.56 | +20.0% | -69.2M |
| 2023 | 509.3M | -5.3% | -207M | -40.6% | -1.95 | -121.6% | -100.4M |
| 2022 | 537.8M | — | -92.5M | -17.2% | -0.88 | — | 9.4M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 13.33 | 14.94 | 11.52 | 11.63 | -11.56% | 15,697,216 | |
| Oct 2026 | 15.81 | 16.44 | 11.85 | 13.15 | -17.55% | 42,474,200 | |
| Sep 2026 | 17.36 | 18.59 | 15.10 | 15.95 | -9.63% | 22,803,500 | |
| Aug 2026 | 15.00 | 18.61 | 15.00 | 17.65 | +18.94% | 26,895,700 | |
| Jul 2026 | 15.38 | 21.45 | 14.83 | 14.84 | -2.05% | 40,738,700 | |
| Jun 2026 | 17.03 | 18.39 | 13.43 | 15.15 | -11.09% | 37,509,500 | |
| May 2026 | 15.48 | 18.92 | 15.35 | 17.04 | +12.03% | 34,341,500 | |
| Apr 2026 | 11.03 | 15.52 | 10.14 | 15.21 | +39.54% | 29,663,900 | |
| Mar 2026 | 13.54 | 14.33 | 10.25 | 10.90 | -20.26% | 29,695,800 | |
| Feb 2026 | 12.28 | 15.46 | 9.82 | 13.67 | +10.24% | 64,086,100 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- NovoCure (NVCR) Stock May Trade At A Discount Despite FDA Setback (opens in a new tab) Simply Wall St. · 12 Nov 2026 23:26
- FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors. (opens in a new tab) Motley Fool · 10 Nov 2026 19:10
- Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31 (opens in a new tab) Benzinga · 10 Nov 2026 18:05
- Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19 (opens in a new tab) Benzinga · 10 Nov 2026 11:29
- Novocure denied FDA approval for metastatic cancer treatment (opens in a new tab) MedTech Dive · 09 Nov 2026 16:40
- Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device (opens in a new tab) Benzinga · 09 Nov 2026 12:26
- Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer (opens in a new tab) 09 Nov 2026 12:00
- Novocure Receives Not Approvable Letter From FDA In Response To PMA Application For Optune Mya For Treatment Of Adult Patients With Brain Metastases From Non-Small Cell Lung Cancer Following Stereotactic Radiation (opens in a new tab) Benzinga · 09 Nov 2026 08:05
- Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock (opens in a new tab) Zacks · 02 Nov 2026 13:15
- NovoCure: 3 Key Takeaways for Long-Term Investors (opens in a new tab) Motley Fool · 02 Nov 2026 02:43
- NovoCure Limited 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 31 Oct 2026 19:05
- NovoCure (NVCR) Q3 Results Spark Margin Turn Debate (opens in a new tab) Simply Wall St. · 31 Oct 2026 08:12
- NovoCure Stock Is In Focus After Earnings Beat And Slower Optune Pax Launch (opens in a new tab) Simply Wall St. · 30 Oct 2026 12:17
- NovoCure Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 29 Oct 2026 20:14
- NovoCure (NVCR) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 29 Oct 2026 18:43
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 11.72 USD
- Market cap
- 1.4B
- Exchange
- NasdaqGS
- Country
- Switzerland
- Sector
- Healthcare
- Industry
- Medical Devices
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow NVCR and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.